Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

CI Financial Corp. ("CI" or the "Corporation") (TSX: CIX) today announced the commencement of the mailing of its management information circular and related shareholder meeting materials for the ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

CI Financial receives an interim court order concerning the transaction under which CI shares will be acquired by an ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

The last round in 2021 valued the healthcare technology firm at $3.2 billion, more than doubling its valuation from $1.3 ...